Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - methadone hydrochloride, quantity: 5 mg/ml - oral liquid, solution - excipient ingredients: glycerol; sodium benzoate; purified water; sorbitol solution (70 per cent) (non-crystallising); ethanol; sunset yellow fcf; flavour - methadone syrup is indicated for the treatment of dependence on opioid drugs.,methadone syrup is indicated for the management of severe pain where: (i) other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and (ii) the pain is opioid-responsive, and (iii) requires daily, continuous, long-term treatment.,methadone syrup is not indicated for use in chronic non-cancer pain other than in exceptional circumstances.,methadone syrup is not indicated as an as-needed (prn) analgesia.,methadone syrup is not recommended for use in ambulant patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - codeine phosphate -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - codeine phosphate hemihydrate, quantity: 30 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate - aspen codeine tablets are indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - lamotrigine -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - oxazepam, quantity: 15 mg - tablet, uncoated - excipient ingredients: magnesium stearate; polacrilin potassium; lactose monohydrate; microcrystalline cellulose - indications as at 22 feb 1995 : management of anxiety disorders or for the short-term relief of the symptoms of anxiety. anxiety associated with depression is also responsive to serepax therapy. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the physician should periodically reassess the usefulness of the drug for the individual patient. alcoholics with acute tremulousness, confusional state or anxiety associated with alcohol withdrawal are reponsive to therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - chloramphenicol, quantity: 10 mg/g - eye ointment - excipient ingredients: wool fat; liquid paraffin; white soft paraffin - indications as at 29 january 2001: for the treatment of bacterial conjunctivitis and other superficial ocular infections caused by chloramphenicol-sensitive organisms.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - amphotericin b, quantity: 10 mg - lozenge - excipient ingredients: acacia; mannitol; polyvinyl alcohol; saccharin sodium; sodium cyclamate; purified talc; stearic acid; flavour - treatment of candidal infections of the oral and perioral areas including oral thrush, angular cheilitis, denture stomatitis and in other conditions of the mouth, throat and tongue complicated by the overgrowth of candida albicans.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - triamcinolone acetonide, quantity: 10 mg/ml - injection, suspension - excipient ingredients: carmellose sodium; polysorbate 80; benzyl alcohol; sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - intra-articular: kenacort-a 10 injection (sterile triamcinolone acetonide suspension usp) is indicated for intra-articular or intrasynovial administration, and for injections into tendon sheaths, as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: synovitis of osteoarthritis, rheumatoid arthritis, acute and subacute bursitis, acute gouty arthritis, epicondylitis, acute non-specific tenosynovitis, post-traumatic osteoarthritis. intradermal: intralesional administration of kenacort-a 10 injection is indicated for the treatment of keloids, discoid lupus erythermatous, necrobiosis lipoidica diabeticorum, alopecia areata and localised hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus ( neurodermatitis), kenacort-a 10 injection also may be useful in cystic tumours of an aponeurosis or tendon ( ganglia).

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - nystatin, quantity: 500000 iu - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate; ethanol; iron oxide yellow; titanium dioxide; gelatin; isopropyl alcohol; shellac; carbon black - indications as at 24 may 2005 : nilstat oral is indicated for the treatment of intestinal candidiasis.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - nystatin, quantity: 500000 iu - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; sodium starch glycollate; ethylcellulose; purified water; carnauba wax; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - indications as at 24 may 2005 : intestinal candidiasis.